الصحة البحوث الطبية الطب القلبية
NEJM
NEJM

@NEJM

11 تغريدة 14 قراءة Apr 10, 2024
Twitter
#ACC24 Round Up: Ten Original Articles were simultaneously published in NEJM and presented at this year’s American College of Cardiology Scientific Sessions in Atlanta. View the full thread for all @ACCinTouch articles and bookmark this post for future reference.
Empagliflozin after Acute Myocardial Infarction (EMPACT-MI) nej.md
Kaplan–Meier estimates of the time to a first hospitalization for heart failure or death from any cause
Empagliflozin after Acute Myocardial Infarction | NEJM
nej.md/4cEb6EB

Empagliflozin after Acute Myocardial Infarction | NEJM

Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2...
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction (AEGIS-II) nej.md
Graph showing the cumulative incidence of a composite of myocardial infarction, stroke, or death from cardiovascular causes through 90 days (primary end point) and through 180 and 365 days (key secondary end points)
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction | NEJM
nej.md/3U4yxzk

Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction | NEJM

Cardiovascular events frequently recur after acute myocardial infarction, and low cholesterol efflux...
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes (STEP-HFpEF DM) nej.md
Graphs showing the change from baseline to week 52 in the dual primary end points
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes | NEJM
nej.md/3TPKpUC

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes | NEJM

Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fra...
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk (Bridge–TIMI 73a) nej.md
Chart showing the effect of the two doses of olezarsen (50 mg and 80 mg) on key lipid outcomes at 6 months, as compared with placebo
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk | NEJM
nej.md/3J8XIum

Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk | NEJM

Reducing the levels of triglycerides and triglyceride-rich lipoproteins remains an unmet clinical ne...
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (Balance) nej.md
Graph of the mean percent changes from baseline in fasting plasma levels of triglycerides
nej.md/43QdO5W

Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome | NEJM

Familial chylomicronemia syndrome is a genetic disorder associated with severe hypertriglyceridemia...
Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock (DanGer Shock) nej.md
Time-to-event curves for death from any cause at 180 days
Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock | NEJM
nej.md/3xyXU3t

Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock | NEJM

The effects of temporary mechanical circulatory support with a microaxial flow pump on mortality amo...
Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction (REDUCE-AMI) nej.md
Graph showing death from any cause or new myocardial infarction (primary end point)
Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction | NEJM
nej.md/4akVhRx

Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction | NEJM

Most trials that have shown a benefit of beta-blocker treatment after myocardial infarction included...
Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus (SMART) nej.md
Panel A: The Kaplan–Meier curve for the first coprimary end point, a clinical composite of death from any cause, disabling stroke, or rehospitalization for heart failure through 12 months, analyzed in the as-treated population (all patients with an attempted implantation procedure, who were included in the analysis according to the first attempted device) Panel B: The Kaplan–Meier estimates of the percentages of patients with bioprosthetic-valve dysfunction through 12 months, the second coprimary end point, a composite of hemodynamic structural valve dysfunction, nonstructural valve dysfunction, clinical valve thrombosis, endocarditis, or aortic-valve reintervention
Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus | NEJM
nej.md/49p7VO7

Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus | NEJM

Patients with severe aortic stenosis and a small aortic annulus are at risk for impaired valvular he...
Transcatheter or Surgical Treatment of Aortic-Valve Stenosis (DEDICATE-DZHK6) nej.md
Kaplan–Meier estimate (stratified according to the criteria of the Society of Thoracic Surgeons) of the risk of the primary outcome
Kaplan–Meier estimate of the risk of death from any cause
Kaplan–Meier estimate of the risk of stroke
Transcatheter or Surgical Treatment of Aortic-Valve Stenosis | NEJM
nej.md/3TLx8MT

Transcatheter or Surgical Treatment of Aortic-Valve Stenosis | NEJM

Among low-risk patients with severe, symptomatic aortic stenosis who are eligible for both transcath...
FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction (FULL REVASC) nej.md
Panel A: Kaplan–Meier estimates of the cumulative incidence of the primary outcome, a composite of death from any cause, new myocardial infarction, or unplanned revascularization. Panel B: The first key secondary outcome, a composite of death from any cause or new myocardial infarction Panel C: the second key secondary outcome of unplanned revascularization
FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction | NEJM
nej.md/3xj5b7u

FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction | NEJM

The benefit of fractional flow reserve (FFR)–guided complete revascularization in patients with ST-s...

التصنيفات

الصحة البحوث الطبية الطب القلبية

لم تظهر جميع التغريدات؟

جاري تحميل الاقتراحات...